HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

April 25, 2024

https://www.globenewswire.com/news-release/2024/04/25/2869506/0/en/HOOKIPA-Pharma-Announces-Pivotal-Phase-2-3-Trial-Design-for-HB-200-in-Combination-with-Pembrolizumab.html

NEW YORK and VIENNA, Austria, April 25, 2024 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ:HOOK, HOOKIPA or the Company), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced its final pivotal Phase 2/3 trial design for HB-200 in combination with pembrolizumab. The Phase 2/3 trial design and protocol are based on alignment with the U.S. Food and Drug Administration (FDA) following the Company’s Type C meeting with the FDA.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.